Company intelligence / Profile preview

Crane Precision Immunotherapy

Shenzhen, Guangdong Sheng, Chinahealthdesign.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Crane Precision Immunotherapy is developing next-generation CAR-T cell therapies targeting hematologic malignancies. Its lead program, a CD7-targeted CAR-T, is in Phase 1 trials for relapsed/refractory T-cell leukemias/lymphomas. The company has at least two additional preclinical or IND-stage assets with immunologic cytotoxicity mechanisms targeting neoplasms. No published efficacy results yet; the main focus is safety/tolerability evaluation.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

CD83 TCR-T

Pre-clinical

Indications: Glioma, Malignant glioma

Partnerships

iCell Gene Therapeutics, Inc.

Beyond the preview

Go deeper on Crane Precision Immunotherapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crane Precision Immunotherapy.

Explore the full profile